Phase II of Zactima Maintenance for Locally Advanced or Metastatic Non-small-cell Lung Carcinoma (NSCLC) Following Platinum-doublet Chemotherapy

Phase 2

Completed

• Conditions: NSCLC
• Interventions: Drug: Placebo; Drug: Vandetanib

• Registration Number: NCT00777179
• Lead Sponsor: Genzyme, a Sanofi Company

Brief Summary

This study is multicenter, randomized, double-blinded, placebo-controlled Phase II study comparing vandetanib (300mg daily) plus best supportive care (BSC) to placebo plus BSC as maintenance treatment in patients with locally advanced or metastatic NSCLC, who have received and responded to prior platinum-doublet systemic chemotherapy. The primary objective of the study is to compare the Progression Free Survival (PFS) rate at 3 months in locally advanced or metastatic NSCLC patients with or without vandetanib maintenance.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-10
• Study First Submitted: 2008-10-21
• Study First Submitted QC: 2008-10-21
• Study First Posted: 2008-10-22
• Primary Completion: 2010-01
• Results First Submitted: 2011-04-27
• Results First Submitted QC: 2011-06-13
• Results First Posted: 2011-07-08
• Study Completion: 2011-12
• Status Verified: 2016-08
• Last Update Submitted: 2016-08-29
• Last Update Posted: 2016-10-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 117

Inclusion Criteria

• Histologic or cytologic confirmation of locally advanced or metastatic NSCLC (IIIb-IV) at the time of original diagnosis.
• Completion of 4 cycles of chemotherapy of gemcitabine (1,000 or 1250mg/m^2/day on day 1 and 8) and cisplatin (70-80mg/m^2/day on day 1) every 3 weeks and have shown response, Complete Response(CR), Partial Response (PR) or stable disease (SD) by RECIST.
• WHO PS 0-1
• No prior radiotherapy to chest, immunotherapy or biologic therapy

Read More

Exclusion Criteria

• Mixed small cell and non small-cell lung cancer history.
• Prior treatment with EGFR TKIs or VEGFR TKIs (prior treatment with cetuximab [Erbitux] or bevacizumab [Avastin] is not permitted.)
• Evidence of severe or uncontrolled systemic disease or any concurrent condition which in the investigator's opinion makes it undesirable for the patient to participate in the study or which would jeopardize compliance with the protocol.
• Radiation therapy within 4 weeks before the start of study therapy. Major surgery within 4 weeks, or incomplete healed surgical incision before starting study therapy.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	-
Vandetanib	Vandetanib	-

Primary Outcome Measures

Name	Time	Method
Progression-free Survival (PFS) Rate at 3 Months	12 weeks	Progression-free survival (PFS) rate at 3 months is defined as the number of patients without evidence of progression or death after 3 months from randomisation among the PFS-evaluable patients.

Secondary Outcome Measures

Name	Time	Method
Overall Survival (OS)	Every 12 weeks unless the patient withdraws consent	Overall survival (OS) defined as the median time from randomization to death from any cause.
Objective Response Rate (ORR)	Performed at baseline, every 4 weeks until Week 12 following randomization and then every 8 weeks until objective disease progression.	Number of patients showing Complete Response (CR) or Partial Response (PR) based on RECIST for the best response.; Number of patients showing Complete Response (CR, disappearance of all target lesions) or Partial Response (PR, at least a 30% decrease in the sum of longest diameter of target lesions taking as reference the baseline sum longest diameter) based on RECIST Criteria Version 1.0 (assessed by CT and/or MRI) for the best response.
Progression-free Survival (PFS)	Performed at baseline, every 4 weeks until Week 12 following randomization and then every 8 weeks until objective disease progression.	Progression-free survival (PFS) defined as the median time from randomization to death from any cause or first observed disease progression.
Disease of Response (DOR)	Performed at baseline, every 4 weeks until Week 12 following randomization and then every 8 weeks until objective disease progression.	Number of patients showing Complete Response (CR), Partial Response (PR) or Stable Disease (SD) based on RECIST for the best response.; Number of patients showing Complete Response (CR, disappearance of all target lesions), Partial Response (PR, at least a 30% decrease in the sum of longest diameter of target lesions taking as reference the baseline sum longest diameter) or Stable Disease (SD, Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as references the smallest sum longest diameter since the treatment started) based on RECIST Criteria Version 1.0 (assessed by CT and/or MRI) for the best response

Trial Locations

Locations (1)

Research Site; 🇰🇷 Seoul, Republic of Korea, Korea, Republic of